Pfizer has been unable to take a big slice of the meningococcal vaccine market with Penbraya and now GSK looks set to consolidate its lead with its new 5-in-1 vaccine.
Pfizer was the first to launch a 5-in-1 meningococcal vaccine, Penbraya, two years ago but failed to capitalize on its advantage, and now rival GSK looks set to confirm its dominance in the field with its new product, Penmenvy.
The 5-in-1 vaccine was approved on 14 February by the US Food and Drug Administration for use in individuals aged...
All eyes on chronic urticaria after eosinophilic esophagitis disappointment.
An updated abstract from the World Conference on Lung Cancer has given analysts confidence in BioNTech’s VEGF-A/PD-L1 bispecific challenger
The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.
